×

Get the Prostate Cancer Patient Guide as a digital download or free mailed copy.

Click here.

09/15/2022

LuPSMA: The Specifics (Part 2)

A whole new form of treatment for metastatic castrate-resistant prostate cancer (mCRPC) is here:  PSMA-targeting therapy.  The first PSMA-targeting therapy approved in the U.S. – with more being tested now in clinical trials – is LuPSMA (177Lu-PSMA-617; Pluvicto®), previously discussed here. We asked medical oncologist and PCF-funded scientist Michael J.. Read More

09/15/2022

LuPSMA: A Whole New Class of Treatment for Prostate Cancer (Part 1)

PSMA is a molecule that sits on the surface of prostate cancer cells, and we can look right at it.  It can’t hide from us – even in bits of cancer no bigger than a grain of rice – because, thanks to research funded by PCF, newly-approved radioactive tracers that. Read More

08/05/2022

Breaking News: FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer

Today, the FDA approved darolutamide in combination with docetaxel chemotherapy for patients with metastatic hormone-sensitive prostate cancer (mHSPC). This means that patients with mHSPC (prostate cancer that has spread beyond the prostate and is responsive to hormone therapy, or who have not yet received hormone therapy) have an additional treatment. Read More

05/18/2022

Metastatic Prostate Cancer: Don’t Accept Complacency!

“This is all we can do” is a phrase no cancer patient wants to hear, especially someone with metastatic disease.  Medical oncologist and PCF-funded investigator Andrew Armstrong, M.D., M.Sc., hears those six words a lot – from patients who have come to see him at Duke University’s Cancer Center, a. Read More

05/10/2022

Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer

If you’ve been diagnosed with metastatic hormone-sensitive prostate cancer (mHSPC), you have many treatment options. Doctors and researchers at the Advanced Prostate Cancer Consensus Conference held in April 2022 in Lugano, Switzerland reviewed the latest clinical trial information and highlighted key points for clinicians. Metastatic prostate cancer means that prostate. Read More

12/21/2016

When Treatment Stops Working: Blame Resistance

In the upside down world of prostate cancer, the good guys want to win the war and the bad guys are leading the resistance. Imagine Rick’s Café in Casablanca, except it’s the bad guys, with a nod from Humphrey Bogart, who are the ones singing “La Marseillaise” – drowning out. Read More

10/12/2016

Treatment for Prostate Cancer: Surgery

The operation to remove the prostate, called a radical prostatectomy, is one of the most difficult surgical procedures there is. There are several reasons for this:  One is simply the prostate’s hard-to-get-to location deep in the pelvis.  Two, there are a lot of blood vessels and important nerves around there,. Read More

10/12/2016

On the Horizon: Radiation Plus Immunotherapy

The body’s immune system has incredible power.  When it turns on something it recognizes as an enemy, its effects can be brutal; just ask anyone suffering from an autoimmune disease. Wouldn’t it be nice if we could somehow harness these cell-killing abilities and use them against cancer?  A great idea. Read More

10/12/2016

How to Find an Expert Radiation Oncologist

Even if hospitals offer the same treatment, by no means does this mean that this treatment is interchangeable. This information can help if radiation is right for you. Read More

10/12/2016

Treatment for Prostate Cancer: External-Beam Radiation Therapy

If you have localized prostate cancer that needs curative treatment, you have two good options:  Radiation and surgery.  (You can read more about surgery here.)  More than 60,000 American men opt for radiation every year, and the cure rates are excellent.  It doesn’t require anesthesia, and this makes it an. Read More